Home › Acute myeloïde leukemie › Californië › Sacramento
Acute myeloïde leukemie klinische studies in Sacramento, CA
12 studies voor Acute myeloïde leukemie zoeken deelnemers op locaties in en rond Sacramento (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruterenFase 2
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
RekruterenFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Mercy Cancer Center - Sacramento, Sacramento
- Woodland Memorial Hospital, Woodland · 16 mijl verwijderd
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekruterenFase 1
- UC Davis, Sacramento
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruterenFase 2
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruterenFase 3
- University of California Davis Comprehensive Cancer Center, Sacramento
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
RekruterenFase 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruterenObservatieonderzoek
- Sutter Medical Center, Sacramento
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
RekruterenFase 2
- University of California Davis Health (UC Davis Health), Sacramento
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RekruterenFase 1/2
- University of California, Davis, Sacramento
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RekruterenFase 2
- University of California Davis Comprehensive Cancer Center, Sacramento
Acute myeloïde leukemie studies in andere steden
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Andere studies in Sacramento
- Niet-kleincellige longkanker29 studies
- Longkanker22 studies
- Borstkanker20 studies
- Prostaatkanker19 studies
- Metastatische kanker16 studies
- Hartfalen12 studies
- Aldermeesklierkanker12 studies
- Kanker (alle vormen)11 studies
- Dikkedarmkanker11 studies
- Blasenkanker10 studies
- Colorectale kanker10 studies
- Type 2-diabetes9 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.